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In the name of Allah, the Beneficent, the 
Merciful
And your Lord inspired the bee: build homes in 
mountains and trees, and in (the hives) they build for 
you [68].
Then eat from all the fruits, following the design of 
your Lord, precisely. From their bellies comes a 
drink of different colors, wherein there is healing for 
the people. This should be (sufficient) proof for 
people who reflect [69].
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ABSTRACT
Background: SLE is a prototype autoimmune disease which can affect many tissues and 
organs of the body. Current treatment with anti-inflammatory and immunosuppressive 
drugs are able to suppress disease activity but associated with significant short term and 
long term side effects. Honey has been shown to have anti-bacterial and anti-
inflammatory properties. However the role of honey in autoimmune diseases has not been
elucidated. We studied the effects of adjuvant honey given together with conventional 
treatment to assess the effect of honey on disease activity and its immunological effects
on lymphocyte function and lymphocyte subsets.
Objectives: To compare the effects of adjuvant honey therapy versus conventional 
therapy alone on disease activity, to determine the effects of adjuvant honey therapy 
versus conventional therapy alone on lymphocyte functions and lymphocyte subsets in 
SLE patients.
Methodology: This was a prospective randomized study. Sixty SLE patients were 
randomized into two equal groups, group 1 receiving conventional treatment with low 
dose steroid and cyclophosphamide or azathioprim, group 2 receiving same treatment in 
addition to honey 20 gm twice a day. Disease activity was measured in all patients every 
3 months by SLEDAI score, C3, C4, ANA titre, dsDNA antibodies and CRP. The 
function of T lymphocyte was determined at baseline and after 6 months by measuring 
the expression of 3 lymphocyte activation markers (HLADR, CD45RO and CD25) using 
flow cytometer. Enumeration of lymphocyte subsets (CD3, CD4, CD8, CD19, and 
XIX
CD16/56) was done by Immunofluorescence staining method using flow cytometer at
baseline and after 6 months. 
Results: SLEDAI score was significantly decreased in honey group compared to non 
honey group after 3 and 6 months of follow up (p value < 0.001, 0.023 respectively). C3 
and C4 showed a significant increase within honey group (p = 0.002, 0.017 respectively).
The level of dsDNA antibodies was found to be decreased significantly within honey 
group (p = 0.05). The level of CRP was found to be decreased significantly within honey 
group compared to non honey group after 6 months follow up ( p = 0.016). For ANA titre 
we observed that the mean difference between the groups after 3 months and after 6 
months follow up was statistically not significant. For the expression of lymphocyte 
activation markers there was a significant decrease in the expression of CD8CD45RO 
and CD8CD25 within honey group compared to non honey group after 6 months follow 
up (p = 0.04, 0.021 respectively). Regarding lymphocyte subsets there was a significant 
increase in CD3 and CD16/56 percentage in honey group after 6 months follow up 
compared with non honey group (p = 0.021, 0.038 respectively). A pattern of increment 
for CD4 and of decrement for CD8 and CD19 was observed in honey group but it was 
not statistically significant.
Conclusion: The use of honey therapy as adjuvant to conventional treatment in patients 
with systemic lupus erythematosus (SLE) was found to be useful in suppressing disease
activity and enhancing lymphocyte function and lymphocyte subsets.
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ABSTRAK
Latar belakang: SLE merupakan prototaip autoimun yang boleh melibatkan banyak tisu 
dan organ badan. Rawatan terkini menggunakan dadah anti-radang dan dadah penindas 
imun berkebolehan untuk menindas aktiviti imun tetapi mempunyai kesan sampingan 
jangkamasa pendek dan jangkamasa panjang yang signifikan. Kami mengkaji tentang 
kesan penggunaan madu yang diberikan bersama rawatan konvensional terhadap
penyakit dan kesan imun dalam fungsi limfosit dan subset limfosit. 
Objektif: Untuk membandingkan kesan diantara terapi tambahan madu dan terapi 
konvensional terhadap aktiviti penyakit berdasarkan skor indeks aktiviti penyakit 
(SLEDAI), untuk membandingkan kesan diantara terapi tambahan madu dan terapi 
konvensional dalam fungsi limfosit, dan untuk membandingkan kesan terapi tambahan
madu dan terapi konvensional dalam subset limfosit dikalangan pesakit SLE.
Prosedur: Dalam kajian prospektif secara rawak ini, semua pesakit di perolehi dari 
Hospital Universiti Sains Malaysia (HUSM), samada mereka yang menghadiri klinik 
pakar atau mereka yang di masukkan ke wad. Enam puluh pesakit SLE dibahagikan sama 
rata kepada dua kumpulan secara rawak, kumpulan pertama menerima rawatan secara 
konvensional dengan dos steroid yang rendah dan cyclophosphamide atau azathioprim, 
kumpulan kedua menerima rawatan yang sama dengan tambahan madu sebanyak 20 gm 
dua kali sehari. Aktiviti penyakit diukur untuk semua pesakit setiap 3 bulan 
menggunakan skor SLEDAI, C3, C4, titer ANA, antibody dsDNA dan CRP. Fungsi T-
limfosit ditentukan pada permulaan kajian dan selepas 6 bulan (dua kali) dengan cara 
mengukur ekspresi 3 penanda pengaktifan limfosit (HLADR, CD45RO dan CD25) 
menggunakan aliran sitometri. Pengiraan subset limfosit (CD3, CD4, CD45, CD19, dan 
CD16/56) menggunakan kaedah fenotaip imun dengan penggunaan aliran sitometri pada 
permulaan kajian dan selepas 6 bulan (dua kali). 
Keputusan: Skor indeks aktiviti penyakit (SLEDAI) menunjukkan penurunan yang 
signifikan dalam kumpulan terapi tambahan madu dibandingkan dengan kumpulan terapi 
bukan madu selepas 3 dan 6 bulan susulan (p value < 0.001, 0.023 masing-masing). 
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Komplimen C3 dan C4 menunjukkan ada kenaikan yang signifikan dalam kumpulan 
terapi madu setelah 6 bulan (p = 0.002, 0.017 masing-masing). Paras CRP didapati 
menurun secara signifikan di dalam kumpulan terapi madu dibandingkan dengan 
kumpulan bukan madu setelah 6 bulan susulan ( p = 0.016). Juga didapati paras antibodi 
dsDNA menurun secara signifikan di dalam kumpulan terapi madu (p = 0.05). 
Untuk ekspresi penanda pengaktifan limfosit (HLADR, CD45RO dan CD25), terdapat 
penurunan yang signifikan dalam ekspresi CD8CD45RO dalam kumpulan terapi madu 
setelah 6 bulan susulan (p = 0.04). Terdapat penurunan yang signifikan dalam ekspresi 
CD8CD25 dalam kumpulan terapi madu setelah 6 bulan susulan (p = 0.021). 
Berkenaan subset limfosit, didapati bahawa wujud kenaikan yang signifikan untuk 
peratus CD3 dan CD16/56 dalam kumpulan terapi madu setelah 6 bulan jika 
dibandingkan dengan kumpulan terapi bukan madu (p = 0.021, 0.038 masing masing).
Corak kenaikan untuk CD4 dan penurunan untuk CD8 dan CD19 dapat dilihat dalam 
kumpulan terapi madu tetapi tidak signifikan secara statistik.
Kesimpulan: Penggunaan terapi tambahan madu keatas rawatan konvensional 
dikalangan pesakit sistemik lupus eritmatosus (SLE) didapati bermanfaat di dalam 
mengurangkan aktiviti penyakit dan menambahbaik fungsi limfosit dan subset limfosit.
1CHAPTER ONE
Introduction
1. Systemic Lupus Erythematosus Overview 
Systemic lupus erythematosus is an autoimmune disease that can affect various parts of 
the body, including the skin, joints, heart, lungs, blood, kidneys and brain. Normally the 
body's immune system makes proteins called antibodies, to protect the body against 
viruses, bacteria, and other foreign materials. 
In an autoimmune disorder like lupus, the immune system cannot differentiate between 
foreign substances and its own cells and tissues. The immune system then makes 
antibodies directed against itself. These antibodies called "auto-antibodies” cause 
inflammation, pain and damage in various parts of the body.
Systemic lupus erythematosus (SLE) is characterized clinically by protean 
manifestations, most commonly including arthralgia, arthritis, rash, alopecia, oral ulcers, 
serositis, leukopenia, central nervous system, and renal involvement (Lahita, 2004). It is 
an important prototype of systemic autoimmunity and it causes significant disability and 
premature death in those patients who suffer from it (Lahita, 2004). It is occasional life 
threatening, often life long, autoimmune disease.
1.1. Epidemiology of SLE 
SLE was previously believed to be a rare disease. Since 1960s, there was an increase in 
the awareness and education about lupus. This has helped many more patients to get an 
accurate diagnosis making it possible to estimate the number of people with lupus.
2The overall prevalence is estimated to be about 1 per 1000. A study from Birmingham, 
UK, found the prevalence to be 27.7/100,000 in the general population, but nearly 9 times 
higher in Afro-Caribbean females (Johnson, Gordon et al., 1995). Data from a national 
health survey in the USA found the self-reported prevalence of SLE (defined as having 
been given a diagnosis of SLE by a physician) to be 241/100,000 (Simard and 
Costenbader, 2007). Recognizing that this may well be an over-estimate, combining self-
reporting with evidence of a current prescription for anti-malarial, corticosteroids, or 
other immunosuppressive medications reduced this figure to 53.6/100,000 (Simard and 
Costenbader, 2007).
Studies carried out in England support the notion that Asians are more predisposed to 
SLE. For example, Asians of Indian, Pakistani and Bangladeshi origins who resided in 
Leicester, England, were three times more likely to develop SLE than Caucasian whites 
(Samanta, Roy et al., 1992). 
In Central Australia, a higher prevalence of SLE was found in Aborigines than Caucasian 
whites (1:1360 versus 1:5170) though the Aborigines were not found to have more 
aggressive disease (Segasothy and Phillips, 2001). 
Population based studies carried out in non-Caucasian countries may provide better 
evidence for ethnic differences in the prevalence of SLE and that certain non- Caucasian 
groups are more susceptible to develop the condition than Caucasian whites. Data from 
China, based on a survey that covered a population of 32 668 carried out in 1984–1985, 
showed the prevalence of SLE was 70.41 per 100 000 persons overall and 113.33 per 100 
000 females according to the 1982 ARA criteria for SLE (Chen, Xu et al., 1987). A study 
3carried out in Hong Kong, where 95% of its population are ethnic Chinese, showed 
comparable figures (58.8 per 100 000 persons overall and 104 per 100 000 females) 
(Mok and Lau, 2003).
Overall, evidence does seem to suggest that SLE is more common in American blacks, 
Hispanics, Afro- Caribbean’s, Native North American Indians and Orientals including 
Asian Indians and Chinese than in Caucasian populations.
1.1.1. Prognosis and survival
Mortality attributed to SLE in the United States in the 1970s and 1980s has shown an 
unfavorable outcome for African-American patients (Siegel and Lee, 1973; Lopez-Acuna 
et al., 1982). The annual age adjusted mortality rate was almost three times higher in 
black females (17.6 per million person-years) than Caucasian white females (6.0 per 
million person-years) (Lopez-Acuna et al., 1982). Similarly, the adjusted annual rates of 
death from SLE between 1968 and 1976 were higher for Asians (Chinese, Japanese and 
Filipinos) (6.8 per million person-years) than Caucasian whites (2.8 per million person-
years) (Kaslow RA, 1982). This was confirmed by other studies in England (Samanta A 
et al., 1991). 
The survival of patients with SLE has improved remarkably in the past few decades and 
five- and 10- years survival rates are now expected in the range of ~95% and ~90% for 
most patients. This improved survival, however, is typical only of the Western world 
whereas in countries such as India (Kumar et al., 1992), and amongst black Caribbean 
patients (Diadyk et al., 1998), poorer survival continues to be recorded. It is not clear 
whether this observation is related to differences in ethnic origin alone. Out of interest the 
4study carried out by Walsh and DeChello (Walsh SJ, DeChello LM, 2001) who attempted 
to identify demographic and environmental factors that affect the incidence and course of 
SLE by studying geographical variation in mortality from the disease in the United 
States. Census data from clusters where there were more or fewer SLE deaths than 
expected were compared. Higher poverty rates and/or greater concentrations of ethnic 
Hispanics were found to be associated with increased mortality from SLE. Thus, it seems 
that both ethnicity and socioeconomic status have an impact on SLE survival. 
1.1.2. Prevalence and disease expression in different racial and gender groups in 
Malaysia
Ethnic Chinese had the highest prevalence of SLE compared to other ethnic groups in 
Malaysia (Wang et al., 1997). There was a high incidence of renal disease in Chinese and 
Malays patients, 74% of patients had significant proteinuria and half of these had 
associated nephrotic syndrome. Indian patients had significantly less incidence of skin 
manifestation compared to other racial groups. No difference in disease expression was 
detected between the ethnic Chinese and Indians and between the male and female 
patients. The overall 5 y and 10 y survival rates were 82% and 70% respectively. Indian 
patients had the poorest survival rates. Survival rates are similar among the Chinese and 
Malay patients (Wang et al., 1997).
1.2. Aetiology of SLE
Evidence suggests that SLE has a multi-factorial aetiology. Sex hormones, environmental 
factors, immunological dysfunction, and genetics have all been hypothesized to be 
5potential causes of SLE (Balow, Boumpas, et al., 2000). Ninety percent of SLE affected
individuals are women. The onset of SLE in women occurs most often during child-
bearing years. This data has led the scientists to hypothesize that estrogen levels during 
child bearing age may be a factor in the development of SLE. Researchers have also 
noted that flares of SLE have been correlated with ultraviolet light photosensitivity, 
which may mean that environmental agents have a role in the onset of SLE. The likely 
environmental triggers include ultraviolet light, drugs, and viruses. These stimuli cause 
the destruction of cells, and expose their DNA, histones, and other proteins, particularly 
parts of the cell nucleus (Blatt and Glick, 1999). However, the most interesting theories 
about the etiology of SLE deal with defects of specific elements of the immune system. 
B cells originate from pluripotent haematopoietic stem cells in the bone marrow and 
undergo several developmental stages before expressing immunoglobulin specific for a 
single antigen. The specificity of the immunoglobulin is determined by rearrangement of 
light chain and heavy chain genes. In a healthy individual, immature B cells undergo a 
"negative selection" process during which B cells that react to self proteins are deleted, 
inactivated, or undergo further gene arrangement. Immature B cells that recognize 
multivalent self antigens are eliminated through clonal deletion. Immature B cells that 
bind to soluble self molecules become anergic. In some cases receptor editing replaces a 
self-reactive immunoglobulin rearrangement with a successive rearrangement.
Theoretically, if the immune system is working properly it should not produce B cells 
with immunoglobulin that react with self proteins such as DNA. However, individuals 
with SLE produce antibodies that react with self proteins (Janeway et al., 1999).
Researches have hypothesized that individuals with SLE may have a defect in the 
6negative selection process during B cell development (Bensimon, Chastagner et al.,
1994). In SLE, the body's immune system produces antibodies against itself, particularly 
against proteins in the cell nucleus. SLE is triggered by environmental factors which are 
unknown (but probably include viruses), in people with certain combinations of genes in 
their immune system.
All the key components of the immune system are involved in the underlying 
mechanisms of SLE, and SLE is the prototypical autoimmune disease. The immune 
system must have a balance (homeostasis) between being sensitive enough to protect 
against infection and being too sensitive and attacking own proteins (autoimmunity) 
(Rahman and Isenberg, 2008).
SLE as a chronic inflammatory disease believed to be a type III hypersensitivity response 
with potential type II involvement, (Hom, Graham et al., 2008).
1.2.1. Genetics
The first mechanism may arise genetically. Research indicates that SLE may have a 
genetic link. Lupus does run in families, but no single "lupus gene" has yet been 
identified. Instead, multiple genes appear to influence a person's chance of developing 
lupus when triggered by environmental factors. The most important genes are located on 
chromosome 6, where mutations may occur randomly or be inherited. Additionally, 
people with SLE have an altered RUNX-1 (a protein that is a transcription factor 
controlling when genes are switched on or off) binding site, which may be either a cause 
or contributor (or both) to the condition. Altered binding sites for RUNX-1 have also 
been found in people with psoriasis and rheumatoid arthritis (Crow, 2008). 
71.2.2. Environmental triggers
The second mechanism may be due to environmental factors. These factors may not only 
exacerbate existing lupus conditions, but also trigger the initial onset. They include 
certain medications (such as some antidepressants and antibiotics), extreme stress, 
sunlight exposure, hormones, and infections. Some researchers have sought to find a 
connection between certain infectious agents (viruses and bacteria) but no pathogens can 
be consistently linked to the disease. UV radiation has been shown to trigger the 
photosensitive lupus rash, but some evidence also suggests that UV light is capable of 
altering the structure of the DNA, leading to the creation of autoantibodies (Rahman and 
Isenberg, 2008).
1.2.3. Drug reactions
Drug-induced lupus erythematosus is a reversible condition that usually occurs in patients 
being treated for a long-term illness. Drug-induced lupus mimics systemic lupus. 
However, symptoms of drug-induced lupus generally disappear once a patient is taken off 
the medication which triggered the episode. There are many medications currently in use 
that can cause this condition, though the most common drugs are procainamide, 
hydralazine and quinidine (Rahman and Isenberg, 2008).
1.2.4. Non-SLE forms of lupus
Discoid (cutaneous) lupus is limited to skin symptoms and is diagnosed via biopsy of 
skin rash on the face, neck or scalp. Often an anti-nuclear antibody (ANA) test for 
8discoid patients is negative or a low-titre positive. About 1-5% of discoid lupus patients 
eventually develop SLE (Hughes, 1998).
1.2.5. Clearance deficiency
The exact mechanisms for the development of systemic lupus erythematosus (SLE) are 
still unclear since the pathogenesis is a multifactorial event. Beside discussed causations, 
impaired clearance of dying cells is a potential pathway for the development of this 
systemic autoimmune disease. This includes deficient phagocytic activity, scant serum 
components in addition to increased apoptosis (Gaipl, Kuhn et al., 2006).
Monocytes isolated from whole blood of SLE patients show reduced expression of CD44 
surface molecules involved in the uptake of apoptotic cells. Most of the monocytes and 
tingible body macrophages (TBM), which are found in the germinal centres of lymph 
nodes, even show a definitely different morphology in patients with SLE. They are 
smaller or scarce and die earlier. Serum components like complement factors, CRP and 
some glycoproteins are furthermore decisively important for an efficiently operating 
phagocytosis. In SLE patients these components are often missing, diminished or 
inefficient.
The clearance of early apoptotic cells is an important function in multicellular organisms. 
It leads to a progression of the apoptosis process and finally to secondary necrosis of the 
cells, if this ability is disturbed. Necrotic cells release nuclear fragments as potential 
autoantigens as well as internal danger signals, inducing maturation of dendritic cells
(DC), since they have lost their membranes integrity. Increased appearance of apoptotic 
cells also is simulating inefficient clearance that leads to maturation of DC and also to the 
9presentation of intracellular antigens of late apoptotic or secondary necrotic cells, via 
MHC molecules (Munoz et al., 2005).
Autoimmunity possibly results by the extended exposure to nuclear and intracellular 
autoantigens derived from late apoptotic and secondary necrotic cells. B and T cell
tolerance for apoptotic cells is abrogated and the lymphocytes get activated by these 
autoantigens; inflammation and the production of autoantibodies by plasma cells are 
initiated (Gaipl et al., 2007).
1.2.6. Accumulation in germinal centres (GC)
In healthy conditions apoptotic lymphocytes are removed in germinal centres by 
specialized phagocytes, the tingible body macrophages (TBM); that’s why no free 
apoptotic and potential autoantigenic material can be seen. In some patients with SLE 
accumulation of apoptotic debris can be observed in GC, because of an ineffective 
clearance of apoptotic cells. In close proximity to TBM, follicular dendritic cells (FDC) 
are localized in GC, which attach antigen material to their surface and in contrast to bone 
marrow-derived DC; neither take it up nor present it via MHC molecules. Autoreactive B 
cells can accidentally emerge during somatic hypermutation and migrate into the GC 
light zone. Autoreactive B cells, maturated coincidently, normally don’t receive survival 
signals by antigen planted on follicular dendritic cells and perish by apoptosis. In the case 
of clearance deficiency apoptotic nuclear debris accumulates in the light zone of GC and 
gets attached to FDC. This serves as a germinal centre survival signal for autoreactive B-
cells. After migration into the mantle zone autoreactive B cells require further survival 
signals from autoreactive helper T cells, which promote the maturation of autoantibody 
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producing plasma cells and B memory cells. In the presence of autoreactive T cells a 
chronic autoimmune disease may be the consequence (Gaipl, Kuhn et al., 2006).
1.2.7. Sex hormones
Sex hormones play a part in the pathogenesis of SLE (Clarke et al., 2008). SLE is 
predominantly a female disease (Cervera R, 2003) and typically has a predilection for 
women in their child-bearing years (Cervera, Khamashta et al., 2003). First onset of SLE 
before puberty and after menopause is uncommon (Formiga Moga et al., 1999). In 
addition, patients with Klinefelter’s syndrome, characterized by hypergonadotrophic 
hypogonadism, are prone to the development of SLE (French and Hughes., 1983). These 
observations suggest a role for endogenous sex hormones in disease predisposition.
Abnormal oestrogen metabolism has been demonstrated in patients with SLE of both 
sexes, with an increase in 16α hydroxylation of oestrone, resulting in significantly raised 
16α hydroxyestrone concentrations (Lahita, Bradlow et al., 1979). The 16α metabolites 
are more potent and feminizing oestrogens.
Women with SLE also have low plasma androgens, including testosterone, 
dihydrotestosterone, dehydroepiandrosterone (DHEA), and dehydroepiandrosterone 
sulfate (Jungers, Nahoul et al., 1982). The concentration of androgens correlates
inversely with disease activity (Lahita, Bradlow et al., 1987). Low concentrations of 
plasma testosterone and raised luteinizing hormone (LH) values (Lahita, Bradlow et al.,
1987) have been found in some men with SLE. 
Some studies have found that exogenous exposure to estrogen, either through oral 
contraceptive or oestrogen replacement therapy may increase the incidence of SLE 
(Sanchez-Guerrero, Karlson et al., 1997).
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Taken together, oestrogens may aggravate SLE by prolonging the survival of 
autoimmune cells, increasing T helper type 2 (Th2) cytokine productions and stimulating 
B cells to produce autoantibodies. The inhibition of the Th1 response and the 
enhancement of CD40L expression on lupus T cells may indirectly promote the Th2 
response and lead to further B cell hyperactivity (Mok and Lau, 2003).
                   
Figure 1.1 Pathogenesis of systemic lupus erythematosus. Adapted from Journal of Clinical 
Pathology (Mok and Lau, 2003).
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1.3. Immunopathology of SLE
The basic pathological features of SLE are that of inflammation and blood vessel 
abnormalities, which include band or occlusive vasculopathy, vasculitis, and immune 
complex deposition.
The best characterized organ pathology is in the kidney. By light and 
immunofluorescence microscopy, renal biopsies in patients with SLE display mesangial 
cell proliferation, inflammation, basement membrane abnormalities and immune complex 
deposition, comprising immunoglobulins and complement components. On electron 
microscopy, these deposits can be visualised in the mesangium and the subendothelial or 
subepithelial surface of the basement membrane.
Other organ systems affected by SLE usually display non-specific inflammation or 
vascular abnormalities, although pathological findings are sometimes minimal. 
Inflammation and necrotising vasculitis can rarely be found. Occlusive vasculopathy is a 
common histological feature associated with the presence of antiphospholipid antibodies. 
Atherosclerosis and tissue damage caused by hypertension, corticosteroids, and other 
drugs can be demonstrated in patients with long standing SLE (Roman, Shanker et al.,
2003).
1.3.1. Autoantibodies in SLE
The central immunological disturbance in patients with SLE is autoantibody production. 
These antibodies are directed at several self molecules found in the nucleus, cytoplasm, 
and cell surface, in addition to soluble molecules such as IgG and coagulation factors. 
Antinuclear antibodies are most characteristic and present in more than 95% of patients. 
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Anti-double stranded DNA (ds-DNA) and anti-Sm antibodies are unique to patients with 
SLE. In fact, their presence is included in the classification criteria of SLE (Gilboe and 
Husby, 1999). The Sm antigen is designated as a small nuclear ribonucleoprotein 
(snRNP) and is composed of a unique set of uridine rich RNA molecules bound to a 
common group of core proteins and other proteins associated with the RNA molecules. 
Anti-Sm antibodies react with snRNP core proteins, whereas anti-DNA antibodies bind to 
a conserved nucleic acid determinant widely present on DNA. Anti-DNA antibody titres 
frequently vary over time and disease activity but anti-Sm antibody titres are usually 
constant. 
The most remarkable feature of anti-DNA antibodies is their association with 
glomerulonephritis. Anti-DNA antibodies can be isolated in an enriched form from 
glomerular eluates of patients with active lupus nephritis and anti-DNA antibodies can 
induce nephritis in normal and severe combined immunodeficient mice (Vlahakos, Foster 
et al., 1992, Ehrenstein, Katz et al., 1995) However, the correlation between anti-DNA 
antibodies and lupus nephritis in not complete because some patients with active nephritis 
are negative for anti-DNA antibodies, whereas some patients with persistent high titres of 
anti-DNA may not show renal involvement.
Although an association between certain clinical features of SLE and autoantibodies has 
been well documented, the pathogenicity of these antibodies has not been adequately 
studied. The exact immunological mechanisms for injury remain to be elucidated. The 
pathogenesis of manifestations other than glomerulonephritis is less well understood, 
although immune complex deposition with activation of complement at relevant sites is a 
probable mechanism. This is demonstrated by the frequent association of 
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hypocomplementaemia and signs of vasculitis at the sites of active SLE. Direct antibody 
mediated damage and cell mediated cytotoxicity on target tissues are other possible 
mechanisms (Gompertz et al., 1990).
1.3.2. Disturbances of the immune response
SLE is characterized by a myriad of immune system aberrations that involve B cells, T 
cells, and cells of the monocytic lineage, resulting in polyclonal B cell activation, 
increased numbers of antibody producing cells, hypergammaglobulinaemia, autoantibody 
production, and immune complex formation. It appears that excessive and uncontrolled T 
cell help in the differentiation and activation of autoantibody forming B cells is probably 
a final common pathway.
The activation of B and T cells requires stimulation by specific antigens. Irritating 
chemicals such as pristine, bacterial DNA and cell wall phospholipids, and viral antigens 
can induce anti-DNA antibodies in mice (Hahn, 1998). Moreover, self antigens, such as 
DNA–protein and RNA–protein complexes may induce autoantibody production (James, 
Gross et al., 1995). Environmental antigens and self antigens are taken up by professional 
antigen presenting cells (APCs) or bind to induced antibodies on the surface of B cells. 
Both professional APCs and B cells process the antigens into peptides and present them 
to T cells through their surface HLA molecules. The activated T cells in turn stimulate 
the B cells to produce pathogenic autoantibodies. In addition to contact stimulation, the 
interaction of B and T cells is facilitated by several cytokines, such as IL-10, and requires 
accessory molecules such as those of the CD40/CD40L and B7/CD28/CTLA-4 systems 
to initiate a second signal.
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B cell activation is abnormal in patients with SLE. The number of B cells at all stages of 
activation is increased in the peripheral blood of patients with active SLE (Klinman, 
Shirai et al., 1991). These B cell abnormalities can precede the development of SLE. 
Activated lupus B cells have higher intracytoplasmic calcium responses than controls 
(Liossis, Kovacs et al., 1996). There is also evidence that B cells in patients with SLE are 
more sensitive to the stimulatory effects of cytokines such as IL-6 than non-SLE B cells 
(Linker-Israeli, Deans et al., 1991). Moreover, the phenomenon of epitope spreading has 
been demonstrated in both human and murine SLE (Monneaux and Muller, 2002). Thus, 
it appears that B cells in patients with SLE are more prone to polyclonal activation by 
antigens, cytokines and other stimuli.
Abnormalities in T cell function are also evident in patients with SLE. The total number 
of peripheral blood T cells is usually reduced, probably because of the effects of anti-
lymphocyte antibodies (Bakke, Kirkland et al., 1983). There is a skewing of T cell 
function towards B cell help, leading to enhanced antibody production (Linker-Israeli, 
Quismorio et al., 1990). Experiments have shown that the early events of T cell 
activation are defective in patients with SLE compared with controls (Portales-Perez, 
Gonzalez-Amaro et al., 1997, Fernandez-Gutierrez, de Miguel et al., 1998). Although 
peripheral lupus T cells are activated, both their capacity for proliferation in response to 
mitogenic stimulation and IL-2 production are reduced (Horwitz and Garrett, 1977, 
Alcocer-Varela and Alarcon-Segovia, 1982, Warrington 1988, Linker-Israeli, Bakke et 
al., 1983). The reasons for the defective Th1 responses in SLE remain speculative. Down 
regulation by excessive Th2 cytokines, defective interaction between APCs and T cells, 
the suppressive effects of CD8+ T cells and natural killer (NK) cells, the presence of IL-2 
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inhibitors, and the down regulation of IL-2 receptors are possible mechanisms (Garcia-
Cozar, Molina et al., 1996). Summary of abnormal immune responses in SLE patients are    
shown in Table 1.1.
1.3.3. Cytokine network in SLE
Cytokine profiles in patients with SLE have been studied extensively. Peripheral blood 
mononuclear cells (PBMCs) from patients with SLE proliferate less than controls when 
stimulated with various antigens and mitogens (Horwitz and Garrett, 1977). Supernatants 
from phytohaemagglutinin (PHA) or autologous mixed lymphocyte reaction stimulated 
lupus T cells to produce less IL-2 than control T cells. Lupus T cells are less responsive 
to IL-2 stimulation than normal T cells (Alcocer-Varela and Alarcon-Segovia, 1982; 
Warrington, 1988; Linker-Israeli, Bakke et al., 1983). However, the expression of IL-2 in 
freshly prepared SLE PBMCs was increased compared with control PBMCs (Horwitz, 
Wang et al., 1994). Lupus T cells are capable of producing normal amounts of IL-2 in 
response to optimal stimulation with PHA combined with phorbol esters or with anti-
CD28 antibodies (Garcia-Cozar, Molina et al., 1996; Horwitz, Wang et al., 1994; 
Horwitz, Gray et al., 1998).  As mentioned previously, the impaired in vitro IL-2 
production from lupus T cells is probably the result of many factors, one of which is the 
downregulating effects of certain Th2 cytokines.
The recent discovery of the role played by IL-10 in the pathogenesis of SLE supports this 
hypothesis. IL-10 is a Th2 cytokine that acts as a potent stimulator of B cell proliferation 
and differentiation, and thereby a potential mediator of polyclonal B cell activation in 
SLE. Indeed, studies have shown that spontaneous production of IL-10 from SLE 
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peripheral blood B cells and monocytes is significantly higher than that of controls 
(Llorente, Richaud-Patin et al., 1993; Llorente, Richaud-Patin et al., 1994). The 
expression of IL-10 transcripts is significantly increased in the non-T cell population of 
PBMCs from patients with SLE compared with controls (Csiszar, Nagy et al., 2000). 
Moreover, serum IL-10 concentrations are higher in patients with SLE than in controls 
and are correlated with clinical and serological disease activity and anti-DNA antibody 
titres (Houssiau, Lefebvre et al., 1995; Park, Lee et al., 1998; Grondal, Gunnarsson et al.,
2000). Furthermore, an increased ratio of IL-10 to interferon γ secreting cells in the 
PBMCs of patients with SLE correlates with disease activity (Hagiwara, Gourley et al.,
1996).
The increase in IL-10 production may be a cause of the defective in vitro Th1 response in 
lupus T cells. This is suggested by a study demonstrating that the addition of blocking 
antibodies to IL-10 significantly enhanced the proliferative response of lupus PBMCs 
(Lauwerys, Garot et al., 2000). Conversely, PBMCs from patients with SLE and inactive 
disease cultured with IL-10 showed a significant augmentation of anti-DNA antibody 
production (Tyrrell-Price, Lydyard et al., 2001).
IL-12, a heterodimeric cytokine produced by B cells, macrophages, and dendritic cells, 
promotes cell mediated immune responses but exerts some inhibitory activities on 
humoral responses (Trinchieri, 1994). IL-12 production was found to be impaired in 
stimulated PBMCs from patients with SLE compared with matched controls (Horwitz, 
Gray et al., 1998; Liu and Jones, 1998). The defect in IL-12 production probably lies in 
the monocytes but not the B cells (Liu, Jones et al., 1999). In contrast, the addition of IL-
12 to lupus PBMCs significantly inhibits both spontaneous and IL-10 stimulated 
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immunoglobulin and anti-DNA antibody production (Houssiau, Mascart-Lemone et al., 
1997). Moreover, the production of anti-DNA antibodies by PBMCs from patients with 
SLE and active disease is inhibited by culturing the cells with IL-12 (Tyrrell-Price, 
Lydyard et al., 2001). The results from these studies suggest that dysregulation of the IL-
10 and IL-12 balance plays a crucial role in the impaired cellular immune responses seen 
in patients with SLE.
1.3.4. Defective immune regulation
The clearance of immune complexes by phagocytic cells is defective in patients with 
SLE. This results partly from the reduced numbers of CR1 receptors for complement and 
functional defects of the receptors on cell surfaces (Mir, Porteu et al., 1988; Kiss, Csipo 
et al., 1996). Defective clearance may also result from inadequate phagocytosis of IgG2 
and IgG3 containing complexes. Allelic polymorphisms of the IgG receptors (FcγR) have 
recently been described. Some of the polymorphic alleles (FcγRIIA and FcγRIIIA) are 
associated with lower binding of the Fc portions of IgG2 and IgG3, and hence impaired 
clearance of immune complexes (Dijstelbloem, Bijl et al., 2000). Indeed, the FcγRIIA 
and FcγRIIIA genotypes have been associated with susceptibility to SLE and nephritis in 
certain ethnic groups (Zuniga, Ng et al., 2001). Although consistent results cannot be 
obtained in patients of different ethnicities, impaired immune complex clearance by 
phagocytes is an important pathogenetic mechanism in SLE. 
In one study also demonstrated that non-inflammatory engulfment phagocytosis of 
apoptotic cells is impaired in patients with SLE (Herrmann et al., 1998). Persistently 
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circulating apoptotic waste may serve as an immunogen for the induction of autoreactive 
lymphocytes and as an antigen for immune complex formation.
The synthesis and secretion of pathogenic autoantibodies in SLE is driven by the 
interaction of CD4+ and CD8+ helper T cells, and double negative T cells (CD4− CD8−) 
with B cells (Mohan, Adams et al., 1993). Therefore, cells that normally suppress B cell 
activation, such as CD8+ suppressor T cells and NK cells are defective in their 
suppressive activity. It has been shown that CD8+ T cells and NK cells from patients 
with active SLE are often incapable of down regulating polyclonal immunoglobulin 
synthesis and autoantibody production (Linker-Israeli, Quismorio et al., 1990). One study 
reported that CD8+ T suppressor cell function was impaired in patients with active SLE
(Filaci, Bacilieri et al., 2001). This impaired suppression of B cells may be one factor that 
leads to the perpetuation of the disease.
In normal healthy subjects, overproduction of antibodies is prevented by an idiotype 
network. This network is probably defective in patients with SLE, leading to 
dysregulation of autoantibody production (Sherer and Shoenfeld Y, 2000).  
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Table 1.1 Summary of abnormal immune responses in SLE patients. 
Hyperactivated B cells
 Number of activated B cells producing Ig increased in peripheral blood 
 B cell abnormalities are present in unaffected family members and may precede 
SLE development 
 Lupus B cells are more prone to polyclonal activation by specific antigens 
 Raised IL-6 and IL-10 concentrations may promote B cell hyperactivity 
 B cell responses to activating signals are abnormal
Hyperactivated T cells
 Number of activated T cells increased in peripheral blood 
 Abnormal early events of T cell activation 
 T cell function skewed towards B cell help and Ig production 
 Lupus T cells produce little IL-2 on stimulation
Abnormal phagocytic functions
 Phagocytic cells cannot bind or process immune complexes efficiently 
 Phagocytosis of apoptotic cells impaired
Abnormal immunoregulation
 Defective clearance of immune complexes and apoptotic materials because of 
qualitative or quantitative defects of early complement proteins (C2, C4, C1q), 
Fcγ, CR1, and C1q receptors on cell surfaces 
 Suppressive activity of suppressor T cells and NK cells on activated T and B cell 
network is inadequate 
 Idiotypic control of antibody production is dysregulated
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1.3.5. Apoptosis and SLE
Apoptosis, or programmed cell death, is a process that leads to the ordered destruction of 
cells, avoiding the release of intracellular contents into the extracellular 
microenvironment, where they have a powerful inflammatory effect. Defective apoptosis 
leading to the prolonged survival of pathogenic lymphocytes was thought to be one 
disease mechanism for SLE (Suzuki, Ichino et al., 1998). Apoptotic cells are usually 
cleared by macrophages via a non-inflammatory pathway (Voll RE and I., 1997). 
Apoptotic and necrotic cells are strong candidates as sources of autoantigens that drive 
the autoantibody response in autoimmune diseases.
The fast and efficient uptake of dying cells is of main importance to prevent contact of 
the immune system with intracellular autoantigens (Rovere P, 2000). Defects in the 
clearance of dying cells may contribute to the etiopathogenesis of systemic lupus 
erythematosus (SLE). Increased apoptosis or impaired clearance of apoptotic cell 
material has been implicated in the pathogenesis of human SLE. 
Impaired clearance functions for dying cells may explain accumulation of apoptotic cells 
and subsequently of secondary necrotic cells in various tissues of SLE patients. During 
cell death by necrosis or apoptosis, autoantigens are cleaved or otherwise modified. 
These modifications may render cryptic epitopes immune dominant. Dendritic cells may 
then acquire modified autoantigens, like apoptotic nuclei and chromatin, and 
consequently start an immune reaction. 
Normally, apoptotic cells are swiftly removed by phagocytosis due to surface changes 
induced by the apoptotic process (Savill J, 2002). This prevents the release of 
intracellular constituents, including nucleosomes, which are uniquely formed during 
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apoptosis through cleavage of chromatin by nucleases. However, antibodies against 
nucleosomes are a hallmark of systemic lupus erythematosus (SLE) (Dieker JW, 2002). 
Therefore, disturbances in either apoptosis or the phagocytosis of apoptotic cells have 
been proposed to play a role in the development of autoimmunity, especially in SLE.
The reasons for the defective clearance of apoptotic cells in SLE are not clear. It could be 
the result of quantitative or qualitative defects of the early complement proteins, such as 
C2, C4, or C1q (Walport, Davies et al., 1998). The C1q receptors on the surface of 
phagocytes constitute an extremely important mechanism for the clearance of apoptotic 
cells (Korb and Ahearn, 1997). Patients or mice with homozygous C1q deficiency 
develop autoantibodies and a lupus-like syndrome apparently because of the inability to 
eliminate apoptotic cells effectively, which leads to an increase in the exposure of 
antigens to the immune system (Walport, Davies et al., 1998; Korb and Ahearn, 1997;
Botto, Dell'Agnola et al., 1998). 
1.4. Lymphocyte subsets in SLE
Human lymphocytes may be classified in three main populations according to their 
biological function and their cell surface antigen expression: T lymphocytes, B 
lymphocytes and natural killer cells (NK). T lymphocytes (CD3+), the precursors of 
which originate in the bone marrow and then migrate and mature in the thymus, can be 
subdivided as well in functionally different populations. The most clearly defined of 
these are helper/inducer T cells (CD3+CD4+) and suppressor/cytotoxic T cells 
(CD3+CD8+). T cells produce no antibodies and are the mediators of cell immunity. 
Helper/inducer lymphocytes are a subset of T lymphocytes (CD3 +) that are CD4 + cells. 
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CD3 + CD4 + counts are used to characterize and monitor some forms of 
immunodeficiency and autoimmune diseases.
Suppressor/cytotoxic lymphocytes are a subset of T lymphocytes (CD3 +) that are CD8 +
cells. Suppressor/cytotoxic lymphocyte values lie outside the normal reference range in 
some autoimmune diseases, and in certain immune reactions such as acute graft-versus-
host disease (GVHD) and transplant rejection. The CD8 + subset is elevated in many 
patients with either congenital or acquired immune deficiencies.
CD19 is the broadest lineage- specific surface marker for B cells and it is present on the 
surface of virtually all B lymphocytes, including early B progenitor cells. CD19 
expression is maintained in B- lineage cells that have undergone neoplastic 
transformation. B lymphocytes (CD19+) are the producers of antibodies; they mediate 
humoral immunity particularly effective against toxins, whole bacteria, and free viruses. 
The immunological status of patients can be determined by assessing the level of CD16-
positive natural killer (NK) cells, and a simultaneous detection of other NK- cell markers 
and enumeration of other lymphocyte subpopulations. NK cells (CD3-CD16+CD56+) 
mediate cytotoxicity against certain tumors and virus-infected cells. NK-mediated 
cytotoxicity does not require class I or class II major histocompatibility complex (MHC) 
molecules to be present on the target cell. CD56 is the prototypic marker of human NK 
cells, and it is also expressed by a subset of CD4- positive and CD8- positive T cells in 
peripheral blood (Paglieroni and Holland, 1994).
1.5. Lymphocyte activation markers in SLE
Activation and proliferation of immunocompetent cells is the basic immunologic 
response to alloantigens (Corradin et al., 1977), which could be evaluated by the 
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expression on T cells of CD25, HLA-DR molecules, and by the loss of the high 
molecular mass isoform of the CD45 molecule (CD45RA) and the expression of the low 
molecular mass isoform CD45RO (De Francesco et al., 1996) and thus termed 
‘‘activation antigens.’’
CD25 are naturally occurring immunoregulatory T cells originate in the thymus, 
constitutively express CD25 and comprise 5-10% of murine and approximately 2% of 
human peripheral CD4+ T cells (Shevach, 2002, Baecher-Allan et al., 2001). Within the 
human CD4+ subset only cells coexpressing high levels of CD25 appear to have potent
regulatory function (Baecher-Allan et al., 2001, Wing et al., 2002). The precise role of 
this distinct T cell subset in human autoimmunity is as yet undefined. 
The primary function of HLA-DR is to present peptide antigens, potentially foreign in
origin, to the immune system for the purpose of eliciting or suppressing T-(helper)-cell 
responses that eventually lead to the production of antibodies against the same peptide 
antigen.
CD45RO are memory T cells generated during a primary response appear to survive for 
long periods and are therefore available to provide immediate protection as well as to 
assist in the provision of rapid and effective responses if and when a relevant Ag is re-
encountered (Goldrath and Bevan, 1999).
Such activation antigens are easily evidenced by immunofluorescence assay and flow 
cytometric analysis using monoclonal antibodies (mAbs) as specific reagents. By two-
and three colour immunofluorescent staining it is also possible to identify, within bulk 
lymphocyte cultures, the T-cell subpopulations involved in the activation process. 
Activation of lymphocytes is a complex, yet finely regulated cascade of events that 
